Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 24;14:1190678. doi: 10.3389/fimmu.2023.1190678

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Liu, Wu, Fu, Han, Wang, Zhang, Liang, Tao, Zhang, Shen, Xu, Yin, Chen, Liu, Pan, Liang and Wu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Risk score predicts responses to immunotherapy and chemotherapy. (A) TIDE scores were significantly lower in the high-risk group than in the low-risk group. (B) Risk scores were negatively correlated with TIDE scores. (C) Using the SubMAP algorithm, we inferred the possibility of anti-programmed cell death protein 1(PD1) and anti- cytotoxic T-lymphocyte-associated protein 4 (CTLA4) response immunotherapy in the high and low risk groups. High risk group may respond better to PD-1 treatment (Bonferroni-corrected P = 0.02). (D) The expression level of PD-L1 in the high and low risk groups (E) The expression level of CTLA-4 in high and low risk groups. (F) The box plot of the estimated IC50 for cisplatin. (G) The box plot of the estimated IC50 for methotrexate. (H) The box plot of the estimated IC50 for paclitaxel. (I) The box plot of the estimated IC50 for rapamycin. (J) The box plot of the estimated IC50 for mitomycin. C (K) The box plot of the estimated IC50 for docetaxel. (L) The box plot of the estimated IC50 for lapatinib. (M) The box plot of the estimated IC50 for gemcitabine. (N) The box plot of the estimated IC50 for bleomycin.